Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has ...
Novo Nordisk’s NVO amycretin, which targets GLP-1 and amylin in one molecule, generated 24% placebo-adjusted weight loss in a ...
The two-time Super Bowl winning quarterback watched his former New York Giants go 3-14 this season. Despite whispers of coaching and front office changes in the lead up to season’s end, the franchise ...
Kyverna Therapeutics Inc., a clinical-stage biopharmaceutical company, has appointed Naji Gehchan, M.D., MBA, as Chief ...
All told, Lilly stock still gained 33% in 2024, outperforming the S&P 500 and Nasdaq Composite. Unfortunately, Lilly ...
In the first half of 2024, it seemed Eli Lilly (NYSE: LLY) could do no wrong. Is Eli Lilly a good stock to buy on the dip? On Jan. 14, CEO David Ricks told investors that 2024 sales would come in at ...
Eli Lilly (NYSE: LLY) began a roll in late 2020 that lasted almost four years. During that time, it became the world's ...
Following a rough fourth quarter, we see the healthcare sector overall as undervalued, with a median discount to our fair ...
Eli Lilly's stock dipped due to cutting Q4 sales targets, despite a strong 2024 performance from Mounjaro and Zepbound. Click ...
Eli Lilly and Company (NYSE:LLY) 43rd Annual J.P. Morgan Healthcare Conference January 14, 2025 5:15 PM ETCompany ParticipantsDave Ricks - Chairman ...
Scorpion Therapeutics Inc. is selling its lead drug in testing for breast cancer and other advanced solid tumors, to Eli ...
The company states: “Eli Lilly (LLY) and Scorpion Therapeutics announced a ... The new company will be led by Dr. Friedman and members of the current Scorpion management team and will focus on ...